TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00815100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
Study: NCT02522598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: water for injection
Study: NCT00604032
Drug: Atralin (tretinoin) Gel, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
Study: NCT00982930
Drug: Tobramycin inhalation powder
Normalized name: Tobramycin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
Study: NCT01044446
Drug: glucose-based peritoneal dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: original exchange frequency
Study: NCT00888069
Drug: CTAP101 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral administration
Study: NCT00888069
Drug: CTAP101 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: single IV injection
Study: NCT02995122
Drug: BAY987516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-090)
Study: NCT02995122
Drug: SPF Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT04671069
Drug: MGL-3196
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
Study: NCT00255957
Drug: Hydroxy Ethyl Starch administration to stroke patients
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03846102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0,9% for injection/infusion.
Study: NCT03846102
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 milligram tablet
Study: NCT02775955
Drug: RX0041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT02170025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received matching placebo tid.
Study: NCT01435863
Drug: SP-02L (darinaparsin for injection)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study: NCT01435863
Drug: SP-02L (darinaparsin for injection)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study: NCT01435863
Drug: SP-02L (darinaparsin for injection)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Study: NCT01389193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
Study: NCT01263314
Drug: MK-8266
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules, 0.1 mg potency
Study: NCT01263314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsules to match MK-8266 capsules
Study: NCT00545480
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 12 months (with feedback)
Study: NCT00545480
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 12 months (without feedback)
Study: NCT00559416
Drug: Cell Transfer
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02465255
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02465255
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03167541
Drug: Test
Normalized name: Testro
Approvals — FDA: no, EMA: no, PMDA: no
Description: RB naproxen sodium tablets (2x220mg)
Study: NCT03167541
Drug: Reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleve naproxen sodium tablets (2x220mg)
Study: NCT03862495
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1g administered as a single oral dose
Study: NCT03933280
Drug: Benoxinate Hydrochloride 0.4% Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
Study: NCT01472991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be taken once daily for 4 weeks
Study: NCT00520637
Drug: EZN-2208
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02563925
Drug: HER2 directed therapy
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03745300
Drug: SIMVASTATIN
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scaling and Root Planing (SRP) followed by placement of simvastatin gel
Study: NCT03745300
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and Root Planing (SRP) followed by placement of placebo gel
Study: NCT00947843
Drug: aspirin + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01429454
Drug: Omega-3 Long Chain Fatty Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: : The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
Study: NCT01429454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
Study: NCT01690884
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
Study: NCT00909519
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500 mg bid
Study: NCT00909519
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01148693
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg per 10ml of contrast media
Study: NCT01148693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water
Study: NCT05405244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules, orally administered once
Study: NCT02219711
Drug: MGCD516
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
Study: NCT02879916
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject 3ml of NaCl 0.9% into the stellate ganglion area
Study: NCT01652937
Drug: BIIB057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04433156
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
Study: NCT03530202
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
Study: NCT01575899
Drug: Clarithromycin-Amoxicillin
Normalized name: AMOXICILLIN/CLARITHROMYCIN/VONOPRAZAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
Study: NCT02261883
Drug: IV Remodulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
Study: NCT02261883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
Study: NCT04460066
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
Study: NCT02708394
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control
Study: NCT01204996
Drug: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
Study: NCT01027013
Drug: placebo eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill one drop in each eye four times daily for 12 weeks.
Study: NCT02205398
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03751423
Drug: IV Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
Study: NCT03751423
Drug: PO Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
Study: NCT03751423
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
Study: NCT00976248
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally once a day
Study: NCT02278081
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the lansoprazole placebo will be taken orally.
Study: NCT02905916
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03246750
Drug: B-MAD chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-MAD chemotherapy
Study: NCT03490032
Drug: [68Ga]-PSMA-R2
Approvals — FDA: no, EMA: no, PMDA: no
Description: radio-labelled PSMA ligand
Study: NCT03618602
Drug: Bisthianostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
Study: NCT01730287
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Hydroxide paste applied.
Study: NCT03345992
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
Study: NCT03289871
Drug: Loceryl 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01100645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipient
Study: NCT00648570
Drug: Lexapro® Tablets (20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, single dose fasting
Study: NCT04213508
Drug: Isotonic Saline ( 0.9% Sodium Chloride Saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
Study: NCT04213508
Drug: Hypertonic Saline ( 3% Sodium Chloride Saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time). So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
Study: NCT00848770
Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.
Study: NCT00848770
Drug: manipulation of SAP
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol or NPS or NOR
Study: NCT01808352
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
Study: NCT00425074
Drug: SR-ASA
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow release acetylsalicylic acid 150 mg
Study: NCT03609489
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
Study: NCT01261260
Drug: Uridine
Normalized name: Uridine
DrugBank: Uridine (DB02745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram tablets BID for 7 days
Study: NCT03983460
Drug: Optimized TCS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
Study: NCT02271009
Drug: AllerT
Normalized name: AllerTan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafast immunotherapy
Study: NCT02271009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo control
Study: NCT01248403
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 10mg (2 x5 mg tablets / day) d1-d28
Study: NCT00381719
Drug: AGN 203818
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg Capsule twice daily for 4 weeks
Study: NCT00381719
Drug: AGN 203818
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Capsule twice daily for 4 weeks
Study: NCT00381719
Drug: AGN 203818
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Capsule twice daily for 4 weeks
Study: NCT00381719
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule twice daily for 4 weeks
Study: NCT02312115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT00168909
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily, oral, for 3 years
Study: NCT00649558
Drug: Actos® Tablets 45 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45mg, single dose fasting
Study: NCT03657810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching CL-108
Study: NCT00054158
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03779633
Drug: Linoladiol Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks
Study: NCT02006498
Drug: Sillymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
Study: NCT02006498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule with same appearances as study drug
Study: NCT05621590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules filled with stevia sweetened powder
Study: NCT01452724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
Study: NCT01452724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
Study: NCT00812604
Drug: Ping On Ointment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ping On Ointment
Study: NCT02268136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02701179
Drug: Lignocaine 1% concentration solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02701179
Drug: Lignocaine 2% concentration solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03617913
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02232594
Drug: Berodual®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03771443
Drug: experimental gluten free toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
Study: NCT00724815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP101 Placebo iontophoretic transdermal patch
Study: NCT01709214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
Study: NCT01226706
Drug: Botulinum Toxins, Type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
Study: NCT01226706
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
Study: NCT00345501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
Study: NCT01306032
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003777
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01478594
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
Study: NCT00813917
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks of placebo (double blinded) by mouth twice per day
Study: NCT04354441
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that is identical in appearance to the study medication will be taken twice a day for 10 days. It will be couriered to participants upon giving consent. They will start taking the medication immediately.